Ciprofloxacin
Links shared publicly online about this topic
MediGuard.org - Ciprofloxacin
mediguard.org — “MediGuard.org - Ciprofloxacin” View full resource at mediguard.org
Most Recently Shared on January 31, 2011 at 2:17 pm By:
MediGuard.org Health Organization
88% of #ciprofloxacin users have NO side-effects ... http://tinyurl.com/4j7xlxt
iGuard.org - Ciprofloxacin Drug Interactions, Ciprofloxacin Side Effects and Ciprofloxacin Patient Reviews
iguard.org — “iGuard.org - Ciprofloxacin Drug Interactions, Ciprofloxacin Side Effects and Ciprofloxacin Patient Reviews” View full resource at iguard.org
Most Recently Shared on March 22, 2010 at 1:17 pm By:
MediGuard.org Health Organization
12% of #ciprofloxacin users getting side-effects ... http://tinyurl.com/yfjc3vh
Allergy/Imm Medical News about Ciprofloxacin
mdlinx.com — “Development of an immunoassay for ciprofloxacin based on phage-displayed antibody fragments” View full resource at mdlinx.com
Most Recently Shared on June 9, 2010 at 8:15 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Development of an immunoassay for ciprofloxacin based on phage-displayed antibody fragments: Journal of... http://bit.ly/9S496B #AI #mdlinx
Popular antibiotic ciprofloxacin linked to UK deaths - The Ecologist
theecologist.org — “Millions of us are successfully treated with ciprofloxacin and other fluoroquinolone antibiotics each year. But for some patients the drugs are linked to severe adverse reactions involving terrifying physical and mental health impacts. Andrew Wasley reports” View full resource at theecologist.org
Most Recently Shared on May 23, 2011 at 2:58 pm By:
MuLondon Health Business and Skin and Beauty
News investigation Popular antibiotic ciprofloxacin linked to UK deaths http://bit.ly/lEtQhb
Information for Healthcare Professionals: Fluoroquinolone Antimicrobial Drugs [ciprofloxacin (marketed as Cipro and generic ciprofloxacin), ciprofloxacin extended-release (marketed as Cipro XR and Proquin XR), gemifloxacin (marketed as Factive), levofloxa
fda.gov — “Information for Healthcare Professionals: Fluoroquinolone Antimicrobial Drugs [ciprofloxacin (marketed as Cipro and generic ciprofloxacin), ciprofloxacin extended-release (marketed as Cipro XR and Proquin XR), gemifloxacin (marketed as Factive), levofloxacin (marketed as Levaquin), moxifloxacin (marketed as Avelox), norfloxacin (marketed as Noroxin), and ofloxacin (marketed as Floxin)]” View full resource at fda.gov
Most Recently Shared on December 3, 2011 at 4:23 pm By:
TherapyGirl5 Therapist and Physical Therapist
Beers Criteria http://t.co/NNX6EjCY missing major drug class = fluoroquinolones http://t.co/InxgkkWF
Aradigm Receives FDA Orphan Drug Designation For Ciprofloxacin For Inhalation In Bronchiectasis
medicalnewstoday.com — “Aradigm Corporation (OTCBB:ARDM) (the Company) today announced it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for ciprofloxacin for inhalation for the m” View full resource at medicalnewstoday.com
Most Recently Shared on June 7, 2011 at 3:05 pm By:
MNT Cystic Fibrosis Health News
Aradigm Receives FDA Orphan Drug Designation For Ciprofloxacin For Inhalation In Bronchiectasis http://mnt.to/3WSg #cysticfibrosis
Aradigm Reports Successful ORBIT-1 Bronchiectasis Study With Inhaled Liposomal Ciprofloxacin
medicalnewstoday.com — “Aradigm Corporation (OTCBB:ARDM) (the Company) today announced positive top line data from its recently concluded Phase 2b study (Once-Daily Respiratory Bronchiectasis Inhalation Treatment - ORB” View full resource at medicalnewstoday.com
Most Recently Shared on June 17, 2011 at 4:05 pm By:
MNT Cystic Fibrosis Health News
Aradigm Reports Successful ORBIT-1 Bronchiectasis Study With Inhaled Liposomal Ciprofloxacin http://mnt.to/3Xmt #cysticfibrosis
Aradigm receives FDA IND approval for inhaled liposomal ciprofloxacin
news-medical.net — “Aradigm Corporation today announced it received clearance from the U.S. Food and Drug Administration (FDA) for its inhaled liposomal ciprofloxacin Investigational New Drug (IND) application. The first trial planned under this IND is a Phase 1/2a, multicenter study designed to evaluate the pharmacokinetics, safety, and tolerability of once-daily administration of 150 mg (3 mL) of Ciprofloxacin for Inhalation (CFI, ARD-3100) in pediatric patients with cystic fibrosis (CF) who have a history of chr” View full resource at news-medical.net
Most Recently Shared on May 5, 2010 at 1:05 pm By:
Aradigm receives FDA IND approval for inhaled liposomal ciprofloxacin: Aradigm Corporation today announced it rece... http://bit.ly/cpSI0y
Aradigm Reports Successful ORBIT-1 Bronchiectasis Study with Inhaled Liposomal Ciprofloxacin - Drugs.com MedNews
drugs.com — “Both ARD-3100 Doses Met Primary Endpoint 2 mL Dose Found Equipotent to 3 mL Dose, with Excellent Safety and Tolerability Jun 16, 2011 - Aradigm Corporation (OTC” View full resource at drugs.com
Most Recently Shared on June 16, 2011 at 1:08 pm By:
Drugs and Devices OW OW Health
Aradigm Reports Successful ORBIT-1 Bronchiectasis Study with Inhaled Liposomal Ciprofloxacin: Both ARD-310... http://bit.ly/mBxNZC #drug
Aradigm Doses First Patient In Its Second Phase 2b Clinical Trial Of Inhaled Liposomal Ciprofloxacin In Bronchiectasis Patients
medicalnewstoday.com — “Aradigm Corporation (OTCBB:ARDM) (the Company) announced that it dosed the first patient in the U.S. as part of its ORBIT-1 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) trial, an” View full resource at medicalnewstoday.com
Most Recently Shared on February 25, 2010 at 3:07 pm By:
Aradigm Doses First Patient In Its Second Phase 2b Clinical Trial Of Inhaled Liposomal Ciprofloxacin In Bronchiectasis... http://mnt.to/3y6r
Aradigm Completes Enrollment In Phase 2b Study Of Inhaled Ciprofloxacin For The Management Of Respiratory Infections In Bronchiectasis
medicalnewstoday.com — “Aradigm Corporation (OTCBB:ARDM) announced the last patient was enrolled in a Phase 2b study designed to evaluate the Company's inhaled liposomal ciprofloxacin (CFI, ARD-3100) in patients with non” View full resource at medicalnewstoday.com
Most Recently Shared on March 23, 2011 at 4:05 pm By:
MNT Cystic Fibrosis Health News
Aradigm Completes Enrollment In Phase 2b Study Of Inhaled Ciprofloxacin For The Management Of Respiratory Infections I... http://mnt.to/3SDy
Gastroenterology Medical Article | Comparison of the effects of subinhibitory concentrations of ciprofloxacin and colistin on the morphology of cardiolipin domains in Escherichia coli membranes
mdlinx.com — “Gastroenterology Medical Article: Comparison of the effects of subinhibitory concentrations of ciprofloxacin and colistin on the morphology of cardiolipin domains in Escherichia coli membranes” View full resource at mdlinx.com
Most Recently Shared on March 13, 2012 at 5:28 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Comparison of the effects of subinhibitory concentrations of ciprofloxacin and colistin on the morphology of... http://t.co/CfpL0C35 #GI
Ciprofloxacin prescriptions increase despite C. diff risks | News | Nursing Times
nursingtimes.net — “A Scottish health report has found that prescriptions for the commonly-used antibiotic ciprofloxacin, thought to increase the risk of infection from C. diff, have increased by 30 per cent in four years.” View full resource at nursingtimes.net
Most Recently Shared on January 27, 2010 at 1:01 pm By:
News: Ciprofloxacin prescriptions increase despite C. diff risks http://bit.ly/bgjNes
Aradigm initiates dosing in Phase 2b trial of inhaled liposomal ciprofloxacin formulations in BE patients
news-medical.net — “Aradigm Corporation today announced that it dosed the first patient in the U.S. as part of its ORBIT-1 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) trial, an international, randomized, double-blind, placebo-controlled Phase 2b study designed to evaluate the Company's inhaled liposomal ciprofloxacin (ARD-3100) in patients with non-cystic fibrosis bronchiectasis (BE) under a U.S. IND. This orphan disease indication is a chronic, severe respiratory disease and there are currently no” View full resource at news-medical.net
Most Recently Shared on February 23, 2010 at 1:32 pm By:
Aradigm initiates dosing in Phase 2b trial of inhaled liposomal ciprofloxacin formulations in BE patients: Aradigm... http://bit.ly/abhAXg
Aradigm to present Phase 1 studies of inhaled liposomal ciprofloxacin at 2010 ERS Congress
news-medical.net — “Aradigm Corporation today announced it is presenting data on September 22, 2010, from its Phase 1 studies at the ERS Annual Congress in Barcelona, Spain. The podium presentation elaborates on the pharmacokinetic parameters of ciprofloxacin in the blood and sputum samples that were observed in the healthy volunteers and non-cystic fibrosis bronchiectasis (BE) patients.” View full resource at news-medical.net
Most Recently Shared on September 17, 2010 at 12:08 pm By:
Aradigm to present Phase 1 studies of inhaled liposomal ciprofloxacin at 2010 ERS Congress: Aradigm Corporation to... http://bit.ly/cSDjZx
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
MediGuard.org
Live health insights from 2.5+ million users of MediGuard, the easiest way to get safety alerts and recalls for your medicines.
-
MediGuard.org
Live health insights from 2.5+ million users of MediGuard, the easiest way to get safety alerts and recalls for your medicines.
-
Sandeep Pulim MD
Over 2K medical journal articles & health news summarized and delivered FREE to 35 specialties daily. Oncology, Rheumatology, Cardiology, Neurology, Psychiatry
Advertisement
